###begin article-title 0
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
Germline EPHB2 Receptor Variants in Familial Colorectal Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: GZ BZ TJH TP SG. Performed the experiments: GZ CJ JB AM PL VF LC SS. Analyzed the data: GZ CJ JB. Contributed reagents/materials/analysis tools: GZ SG. Wrote the paper: GZ SG.
###end p 1
###begin p 2
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 653 658 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 1147 1152 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 1162 1170 1162 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 1576 1581 1576 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 1629 1634 1629 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 1049 1057 <span type="species:ncbi:9606">patients</span>
Familial clustering of colorectal cancer occurs in 15-20% of cases, however recognized cancer syndromes explain only a small fraction of this disease. Thus, the genetic basis for the majority of hereditary colorectal cancer remains unknown. EPHB2 has recently been implicated as a candidate tumor suppressor gene in colorectal cancer. The aim of this study was to evaluate the contribution of EPHB2 to hereditary colorectal cancer. We screened for germline EPHB2 sequence variants in 116 population-based familial colorectal cancer cases by DNA sequencing. We then estimated the population frequencies and characterized the biological activities of the EPHB2 variants identified. Three novel nonsynonymous missense alterations were detected. Two of these variants (A438T and G787R) result in significant residue changes, while the third leads to a conservative substitution in the carboxy-terminal SAM domain (V945I). The former two variants were found once in the 116 cases, while the V945I variant was present in 2 cases. Genotyping of additional patients with colorectal cancer and control subjects revealed that A438T and G787R represent rare EPHB2 alleles. In vitro functional studies show that the G787R substitution, located in the kinase domain, causes impaired receptor kinase activity and is therefore pathogenic, whereas the A438T variant retains its receptor function and likely represents a neutral polymorphism. Tumor tissue from the G787R variant case manifested loss of heterozygosity, with loss of the wild-type allele, supporting a tumor suppressor role for EPHB2 in rare colorectal cancer cases. Rare germline EPHB2 variants may contribute to a small fraction of hereditary colorectal cancer.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-delaChapelle1">[1]</xref>
###xml 300 303 300 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYH</italic>
###xml 471 474 471 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-delaChapelle1">[1]</xref>
Colorectal cancer is a common malignancy in Western society, with 15-20% of cases developing on the basis of apparent genetic predisposition [1]. However, the recognized familial colorectal cancer syndromes-Familial Adenomatous Polyposis (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and MYH-Associated Polyposis (MAP)-account for much less than one-third of inherited colorectal cancer, leaving the additional heritable component of this disease unexplained [1].
###end p 4
###begin p 5
###xml 148 151 148 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Powell1">[2]</xref>
###xml 152 155 152 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Shitoh1">[4]</xref>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 355 367 355 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;&#8722;catenin</italic>
###xml 665 669 659 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB</italic>
###xml 674 680 668 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ephrin</italic>
###xml 687 690 681 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Batlle1">[5]</xref>
###xml 692 695 686 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Clevers1">[6]</xref>
In the great majority of colorectal cancers, mutational activation of the WNT signaling pathway plays an essential role in initiating tumorigenesis [2]-[4]. Hyperactivation of WNT signaling most commonly occurs early in the adenoma to carcinoma sequence as a consequence of inactivating mutations in the APC tumour suppressor gene or activating oncogenic beta-catenin mutations. These genetic alterations lead to constitutive activation of beta-catenin /TCF4 complex which, in turn, drives overexpression of WNT signaling targets. These downstream effectors of the WNT pathway include genes with a critical role in the development of colorectal tumors, such as the EPHB and ephrin genes [5], [6].
###end p 5
###begin p 6
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 248 251 248 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Praml1">[7]</xref>
###xml 409 412 409 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Ogunbiyi1">[8]</xref>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 646 649 646 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Alazzouzi1">[9]</xref>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Jubb1">[10]</xref>
###xml 384 389 <span type="species:ncbi:9606">human</span>
A role for EPHB2, a member of the Eph receptor tyrosine kinase family, as a tumor suppressor gene in colorectal carcinogenesis has been suggested by several recent findings. EPHB2 maps to a chromosomal region (1p36.1) often deleted in these tumors [7]. In addition, immunohistochemical studies have shown that expression of multiple EPHB isoforms is frequently suppressed in invasive human colorectal tumours [8]. Moreover, Alazzouzi et al. have recently shown a high incidence of EPHB2 frameshift mutations in microsatellite unstable colorectal tumors and aberrant EPHB2 promoter methylation in both microsatellite stable and unstable neoplasms [9]. Loss of EPHB2 expression in colorectal tumors has also been associated with worse prognosis [10].
###end p 6
###begin p 7
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Huusko1">[11]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Kittles1">[12]</xref>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 1196 1201 1196 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 275 278 <span type="species:ncbi:9606">men</span>
Mutational inactivation of EPHB2 has been linked to prostate carcinogenesis. Huusko et al. recently described a variety of EPHB2 mutations in prostate tumours and in cell-lines [11], and a common nonsense mutation has been associated with prostate cancer in African American men with a family history of this disease [12]. These findings taken together with the established role of EPHB receptors in colorectal cancer, prompted us to hypothesize that germline EPHB2 mutations may account for at least a fraction of the genetic alterations underlying the unexplained portion of hereditary colorectal cancer, and may represent a new cancer syndrome causing genetic predisposition to colorectal and prostate cancer. Therefore, in this study, we screened 116 population-based familial colorectal cancer cases for germline EPHB2 mutations. The 116 probands tested had at least one additional affected first degree relative. These cases had microsatellite stable tumors, and did not meet diagnostic criteria for FAP, HNPCC and MAP. We also enriched our series with individuals who met the above inclusion criteria and had personal or family histories of prostate cancer. Our findings suggest that rare EPHB2 alleles contribute to a small fraction of familial colorectal cancer.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
Study Subjects and DNA Samples
###end title 9
###begin p 10
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Cotterchio1">[13]</xref>
Biospecimens were obtained from the Ontario Familial Colorectal Cancer Registry (OFCCR), a member of the National Cancer Institute Cooperative Family Registries for Colorectal Cancer Studies () [13]. The OFCCR includes 3,770 colorectal cancer cases diagnosed in the province of Ontario, Canada between 1997-2000, with an age at the time of diagnosis of 20 to 74. Age- and sex-matched control subjects with no personal history of colorectal cancer were recruited by telephone from a list of randomly selected residential telephone numbers for Ontario and from population-based Tax Assessment Rolls of the Ontario Ministry of Finance. Study subjects donated a venous blood sample and peripheral lymphocytes were isolated using Ficoll-Paque, according to the manufacturer's recommendations (Amersham Biosciences, Baie d'Urfe, Quebec, PQ, Canada). The phenol-chloroform method was used to isolate genomic DNA from lymphocytes and colorectal cancer cell-lines. The QIAamp protocol (Qiagen Inc., Mississauga, Ontario, Canada) was employed to extract genomic DNA from paraffin-embedded tissues. All study subjects signed written consent to participate in a Mount Sinai Hospital Research Ethics Board approved research study.
###end p 10
###begin title 11
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
EPHB2 Mutation Screening
###end title 11
###begin p 12
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 807 815 807 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002885.s001">Table S1</xref>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">Patients</span>
Using automated sequencing (Applied Biosystems 3730xl DNA Analyzer, Foster City, CA, USA), we screened for germline EPHB2 (Entrez Gene ID: 2048; RefSeq: NM_004442, NM_017449) sequence variants in 116 familial colorectal cases (average age at diagnosis 54 years, range 22 to 74 years, 59 females, 57 males). Our analysis included patients with personal (n = 6) and/or family histories (father, n = 19; sibling, n = 23; half-sibling, n = 4) of prostate cancer. Patients with FAP, HNPCC or MAP were excluded. A series of colorectal cancer cell lines (Caco2, Colo320DM, Colo320HSR, HT29, LS513, LS1034, SW837, SW948, SW1417, T84) were also screened. We sequenced the entire coding region and at least 50 bp of intronic sequence at the exon/intron boundaries. PCR primer sequences and conditions are provided in Table S1. Variants identified are numbered relative to RefSeq NM_004442.
###end p 12
###begin title 13
A438T, D679N and G787R Allele Frequencies
###end title 13
###begin p 14
###xml 594 598 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Mira1">[14]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Mira1">[14]</xref>
###xml 639 647 639 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002885.s002">Table S2</xref>
A random sample of cases and matched controls from the OFCCR series were selected for studies to evaluate the A438T, D679N and G787R allele frequencies. Lymphocyte DNA samples from an additional series of OFCCR cases (n = 364 for A438T; n = 1160 for D679N; n = 182 for G787R) and population-matched controls (n = 384 for A438T; n = 1133 for D679N; n = 199 for G787R) were tested to evaluate the population frequencies of the A438T, D679N and G787R variants. Genotyping assays for the A438T, D679N and G787R variants were developed using Fluorescence Polarization-Single Base Extension (FP-SBE) [14], SNPstream [14] and RFLP, respectively (Table S2).
###end p 14
###begin title 15
Pedigree and Loss of Heterozygosity (LOH) Analyses
###end title 15
###begin p 16
###xml 430 438 430 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002885.s002">Table S2</xref>
Testing for segregation in the families of the probands carrying the A438T and G787R variants was performed by direct sequencing, using either lymphocyte or archival DNA from paraffin-embedded tissue blocks. Loss of heterozygosity was performed by sequencing paired tumor/normal archival DNA samples and comparing sequence autoradiograms for a decrease in the intensity of the non-mutated signal compared to the mutated sequence (Table S2). These reactions were performed using the Thermo Sequenase Radiolabeled Terminator Cycle Sequencing kit, according to the manufacturer's protocol (USB Corporation, Cleveland, Ohio, USA).
###end p 16
###begin title 17
Biochemical Characterization of the A438T & G787R Variants
###end title 17
###begin p 18
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A438T</italic>
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G787R</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A438T</italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G787R</italic>
###xml 981 985 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Henkemeyer1">[15]</xref>
###xml 1160 1168 1156 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1322 1327 1318 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1329 1333 1325 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Holland1">[16]</xref>
The A438T and G787R cDNA sequence variants were generated using PCR-based site-directed mutagenesis and RefSeq NM_004442 (OriGene Technologies Inc., Rockville, MD, USA) as the template. The PCR products were cloned into pcDNA3 (Invitrogen Canada Inc.), and sequence verified. DU145 (a gift from Dr. Irene Andrulis, Samuel Lunenfeld Research Institute) were grown in MEM/10% FBS. Cells were transiently transfected with the various EPHB2 cDNA constructs (wild-type, A438T, or G787R) using lipofectamine 2000 (Invitrogen Canada Inc., Burlington, Ontario, Canada), according to manufacturers instructions. Five hours following transfection, medium was changed to starvation medium (MEM/0.5%FBS) for 16h. Cells were then stimulated with 2 microg/ml preclustered ephrin b1-Fc (ephrin b1-Fc, R&D Systems, Minneapolis, MN, USA; anti-Fc antibody, Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) for 30min. Transfected EPHB2 was immunoprecipitated using anti-EPHB2 antiserum [15] and immunoblotted with anti-phosphotyrosine (4G10, Upstate Biotechnology, Lake Placid, New York, USA) or anti-EPHB2. Expression and immunoprecipitation of EPHB2 variants for in vitro kinase assays was performed as above except cells were left unstimulated prior to cell lysis and immunoprecipitation, as previously described by Holland et al. [16] Gels were analyzed and quantified using a Storm phosphoimager (Molecular Dynamics Inc., Sunnyvale, California, USA).
###end p 18
###begin title 19
Results
###end title 19
###begin p 20
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Huusko1">[11]</xref>
###xml 235 242 235 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002885-t001">Table 1</xref>
###xml 489 494 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
Mutational screening of the EPHB2 gene in 116 patients with familial colorectal cancer identified 3 novel missense nucleotide changes and the D679N variant previously suggested by Huusko et al.[11] to be pathogenic in prostate cancer (Table 1). Three unrelated patients were found to carry the D679N allele, diagnosed with colorectal cancer at the ages of 57, 59 and 67 years, respectively. However, subsequent analysis of additional subjects suggests that D679N represents a rare neutral EPHB2 polymorphism, since the variant allele was observed at similar frequencies in patients with colorectal cancer (11 out of 1133) and population-matched controls (11 out of 1160).
###end p 20
###begin title 21
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
Non-synonymous germline EPHB2 missense changes identified in familial and random colorectal cancer cases.
###end title 21
###begin p 22
A conservative residue substitution (V945I).
###end p 22
###begin p 23
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
We also screened for EPHB2 mutations in 10 colorectal cancer cell lines, and Caco2 was found to express a novel variant, R4Q (nt. 11 A-->G), in addition to the wild-type EPHB2 receptor. The R4Q amino acid substitution may cause an alteration in the signal peptide, which may lead to decreased EPHB2 expression. However, immunoprecipitation with anti-EPHB2 antiserum, followed by immunoblotting using an antiphosphotyrosine antibody, demonstrated that despite carrying the R4Q variant, the CAC02 cell line produces a functional EPHB2 receptor (data not shown).
###end p 23
###begin p 24
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Skorstengaard1">[17]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-WybengaGroot1">[18]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Pasquale1">[19]</xref>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
Two of the three novel nonsynonymous variants (A438T & G787R) we identified result in biochemically significant and potentially pathogenic residue changes. The residue affected by the A438T substitution is located in the extracellular fibronectin type III domain [17]. Since this domain may be involved in ligand binding, we postulated that the A438T variant might have decreased binding activity and signaling function. The G787R variant affects a residue in the kinase domain, and this substitution might therefore directly affect the receptor's kinase and biological activity [18]. The third novel variant (V945I) was detected in two patients, and leads to a conservative substitution at the extreme carboxy-terminus in the SAM domain [19]; we have not characterized this allele further.
###end p 24
###begin p 25
###xml 207 216 207 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g001">Figure 1A</xref>
###xml 530 539 530 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g001">Figure 1A</xref>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 826 831 826 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 948 951 948 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Praml1">[7]</xref>
###xml 953 956 953 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Ogunbiyi1">[8]</xref>
###xml 999 1004 999 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 33 40 <span type="species:ncbi:9606">patient</span>
The A438T variant was found in a patient who had two primary cancers. He was diagnosed with prostate cancer and a microsatellite stable right-sided colon cancer at the ages of 61 and 64 years, respectively (Figure 1A, Family 1). The proband's father also carried the A438T variant and is the only other family member with colon cancer, he was diagnosed with a microsatellite stable sigmoid cancer at the age of 76 years. Of the 6 unaffected family members tested for this missense change, 3 were found to carry the A438T variant (Figure 1A). Sequencing analyses of paired tumor-normal genomic DNA samples revealed loss of the wild-type EPHB2 allele in the colon cancer from the proband, but not in the colon cancer from his father (data not shown). The father's tumor manifested LOH of the variant, rather than the wild-type, EPHB2 allele. This latter observation may reflect the frequent loss of the 1p36.1 chromosomal region during tumorigenesis [7], [8], and not the targeted inactivation of the EPHB2 locus by LOH.
###end p 25
###begin title 26
Pedigrees of colorectal cancer cases carrying the A438T (Family 1, Panel A) and G787R (Family 1, Panel B) variants.
###end title 26
###begin p 27
+/-, carrier; -/-, non-carrier; LOH+, Colorectal tumour tissue was found to manifest LOH, with loss of the wild-type allele; Ca, cancer.
###end p 27
###begin p 28
###xml 102 111 102 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g001">Figure 1B</xref>
###xml 172 180 172 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g002">Figure 2</xref>
###xml 515 522 515 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 533 542 533 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g001">Figure 1B</xref>
###xml 36 43 <span type="species:ncbi:9606">patient</span>
###xml 187 194 <span type="species:ncbi:9606">patient</span>
The G787R variant was detected in a patient with a diagnosis of rectal cancer at the age of 67 years (Figure 1B, Family 2). This tumor showed loss of the wild-type allele (Figure 2). The patient also reported a history of follicular type thyroid cancer at age 73 years. This proband was selected for mutation screening because of a family history of colorectal cancer on the maternal side. However, genotyping data revealed that the G787R variant allele either originates on the paternal side or is the result of a de novo mutation (Figure 1B). The proband's daughter is the only other carrier of this variant, and she is currently unaffected at the age of 45 years.
###end p 28
###begin title 29
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
Sequencing results demonstrating loss of the wild-type EPHB2 allele in the G787R carrier. EPHB2 gene sequencing results of genomic DNA extracted from paired tumor and adjacent normal colon mucosa are shown.
###end title 29
###begin p 30
Relative to the intensities of the guanine bands in the sequencing reaction, the intensity of the guanine nucleotide at position 2359 is substantially reduced in the tumor sample, suggesting loss of the wild type allele (G) in the tumor but not in the adjacent normal tissue (arrow shows nt. 2359).
###end p 30
###begin p 31
###xml 261 268 261 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002885-t001">Table 1</xref>
We estimated the allele frequencies of the A438T and G787R variants by screening an additional series of population-based colorectal cancer cases and age and sex matched control subjects. The genotyping results suggest that these two alleles are rare variants (Table 1). Neither variant was detected in control subjects and they were not identified in any additional colorectal cancer cases. Therefore, to further evaluate the possible pathogenic role the A438T and G787R receptor variants, we characterized their intrinsic tyrosine kinase activity.
###end p 31
###begin p 32
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Huusko1">[11]</xref>
###xml 526 535 526 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g003">Figure 3A</xref>
###xml 806 815 806 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002885-g003">Figure 3B</xref>
Biochemical characterization of the A438T and G787R isoforms revealed that that the G787R variant is functionally impaired, whereas the A438T change likely represents a neutral polymorphism. DU145 cells, which do not express an endogenous functional EPHB2 receptor [11], were transiently transfected with either the wild-type EPHB2 receptor or one of the two variants. We found diminished autophosphorylation of the G787R receptor, but not the A438T variant, following ephrinB1 stimulation compared to the wild-type receptor (Figure 3A). We confirmed that the G787R receptor has reduced catalytic activity by using an in vitro kinase assay. The ability of the G787R receptor to autophosphorylate or to phosphorylate the enolase substrate was approximately 9-fold lower than that of the wild-type receptor (Figure 3B), demonstrating that the G787R mutation alters receptor activity and is not a rare neutral polymorphism.
###end p 32
###begin title 33
Biochemical characterization of EPHB2 variants.
###end title 33
###begin p 34
###xml 0 99 0 99 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Panel A: Diminished autophosphorylation of EPHB2 G787R variant in response to ephrinB1 stimulation.</underline>
###xml 538 596 538 596 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Panel B: Abolished kinase activity of EPHB2 G787R variant.</underline>
###xml 887 889 887 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1130 1133 1126 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
Panel A: Diminished autophosphorylation of EPHB2 G787R variant in response to ephrinB1 stimulation. DU145 cells were transiently transfected with cDNA constructs (empty vector; wild-type, wt; A438T; G787R) and either left unstimulated (-) or stimulated (+) with preclustered ephrinB1-Fc for 30 min. EPHB2 was immunoprecipitated (IP) and immunoblotted (IB) with antiphosphotyrosine (4G10) to evaluate receptor autophosphorylation. The cell lysate was immunoblotted with antiEPHB2 to ascertain that there was equal transfection efficiency. Panel B: Abolished kinase activity of EPHB2 G787R variant. In vitro kinase assays were performed using wild-type EPHB2 or G787R immunoprecipitates and enolase as the exogenous substrate. Prior to imaging or immonoblotting against EPHB2, phosphorylated proteins were separated by gel electrophoresis and stained with coomassie. Autoradiogram showing 32PgammaATP incorporation in EPHB2 and enolase (upper panel), anti-EPHB2 immunoblot (middle panel) and equal loading of enolase is shown (lower panel). The table shows the relative kinase activity of the wild-type EPHB2 receptor (set to 100%) vs. the G787R variant.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Pasquale1">[19]</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Aasheim1">[20]</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Pasquale1">[19]</xref>
The Eph receptor family is the largest known subgroup of receptor tyrosine kinases. This family is further subdivided into two distinct classes, EphA (A1 to A10) and EphB (B1 to B6), based on their binding affinities for two membrane-anchored ligand families with the corresponding names of type A (A1 to A5) and B (B1 to B3) ephrins [19], [20]. Following ligand binding, Eph receptors activate cell repulsion pathways to modulate cell compartmentalization and ordered cell migration in a variety of biological processes [19].
###end p 36
###begin p 37
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Holmberg1">[21]</xref>
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Batlle1">[5]</xref>
###xml 757 760 757 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Batlle1">[5]</xref>
###xml 762 765 762 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Clevers1">[6]</xref>
###xml 767 771 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Holmberg1">[21]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Batlle2">[22]</xref>
###xml 915 920 915 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphB2</italic>
###xml 924 929 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphB3</italic>
###xml 946 951 946 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
Mouse animal model studies have shown that, in the small intestine, EphB receptors mediate intestinal stem cell proliferation [21] as well as epithelial cell migration and organization along the crypt-villous axis [5]. Since loss of mitotic activity control, epithelial patterning and tissue architecture are hallmarks of tumorigenesis, disruption of normal EPHB receptor expression and function likely promotes colorectal carcinogenesis. Constitutive EPHB receptor expression may stimulate tumor initiation by disturbing proliferative stem cell homeostasis, and secondary silencing of EPHB receptor activity may permit expansion of cancer cells, beyond the spatial boundaries imposed by intact EPHB receptor function to populate adjacent tissue structures [5], [6], [21]. In support of this hypothesis, we and others have recently shown a causal role for EphB inactivation in tumor progression [22]. We found that EphB2 or EphB3 silencing in ApcMin/+ mice results in accelerated and more aggressive colorectal tumorigenesis.
###end p 37
###begin p 38
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Huusko1">[11]</xref>
###xml 980 988 <span type="species:ncbi:9606">patients</span>
###xml 1246 1253 <span type="species:ncbi:9606">patient</span>
In the current study, we screened 116 population-based familial cases of colorectal cancer for mutations in a candidate tumor suppressor gene, EPHB2, and identified three candidate variants (A438T, D679N, G787R), which were further characterized. Even though the A438T allele was not observed in control subjects and was found to segregate with disease in Family 1, biochemical characterization suggests that A438T is a rare neutral polymorphism; we cannot exclude the possibility that it affects more subtle aspects of EPHB2 signaling, such as the formation of higher order oligomers. The D679N variant has been previously reported to be associated with prostate cancer [11]. Although, it remains possible that this variant modulates predisposition to prostate cancer, our data suggest that it occurs at a population frequency of approximately 1% and that it does not, on its own, increase susceptibility to colorectal cancer. We observed the D679N allele in a similar number of patients with colorectal cancer and population-matched controls. In contrast to these latter variants, our data suggest that the G787R variant is functionally compromised and may be a rare cause of hereditary colorectal cancer. The G787R variant was identified in a patient diagnosed with rectal cancer at 67 years of age, and biochemical characterization revealed that the G787R substitution markedly diminishes the receptor's intrinsic kinase activity.
###end p 38
###begin p 39
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Oba1">[23]</xref>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 656 661 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 735 741 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 757 762 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 925 930 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 981 987 981 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1059 1063 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002885-Kokko1">[24]</xref>
###xml 1620 1625 1620 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 1791 1796 1791 1796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 1163 1171 <span type="species:ncbi:9606">patients</span>
###xml 1387 1395 <span type="species:ncbi:9606">patients</span>
###xml 1639 1647 <span type="species:ncbi:9606">patients</span>
There have been two other investigations examining the contribution of germline EPHB2 mutations to colorectal cancer susceptibility. Oba et al. screened for EPHB2 mutations in colon tumors and respective normal colon tissues from 50 patients with colorectal cancer, and identified an intron 8 alteration in a single tumor sample, which results in a nonsense mutation. However, it is unclear if this is a somatic mutation, as there is no indication whether this genetic change was also observed in the paired normal colon sample [23]. This investigation also identified 15 cases with LOH involving the EPHB2 gene and screened for mutations in the remaining EPHB2 allele. Since mutations in the remaining allele were not identified, Oba et al. suggested that EPHB2 is not a classical tumor suppressor gene. However, since only 50 samples of likely sporadic cases of colorectal cancer were analyzed, a tumor suppressor role for EPHB2 cannot be excluded. In a more recent study, Kokko et al. reported an association of three novel variants with colorectal cancer [24]. Germline missense changes resulting in I361V, R568W, and D861N were observed in colorectal cancer patients, but not in healthy controls. However, it is possible that these three variants are rare neutral polymorphisms since the biological significance of the variants was not evaluated using direct functional assays. The patients screened in these latter two studies did not necessarily have significant family histories of colorectal cancer. In contrast to these two earlier reports, our study was designed to specifically evaluate the role of germline EPHB2 mutations in patients with familial colorectal cancer, and not in sporadic cases. Despite study design differences, together these three investigations suggest that EPHB2 germline mutations are not common occurrences in colorectal cancer. Further investigations of larger sample sizes are needed to confirm this observation.
###end p 39
###begin p 40
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB2</italic>
###xml 777 781 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB</italic>
###xml 873 877 873 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHB</italic>
###xml 118 125 <span type="species:ncbi:9606">patient</span>
In summary, we identified a germline EPHB2 variant (G787R) with diminished biological activity in a colorectal cancer patient, and suggest that EPHB2 mutations contribute to a small fraction of hereditary colorectal cancer. The rarity of germline EPHB2 mutations supports a more significant role for EPHB2 in colorectal tumor progression rather than in tumor initiation. Since the EPHB receptors (EPHB2, EPHB3 and EPHB4) follow a similar pattern of transcriptional silencing in colorectal cancers, all EPHB receptor family members probably play a similar role in this disease. Therefore, the EPHB family likely accounts for a minor proportion of genetic predisposition to colorectal cancer but has an important role in tumor progression. Although our findings suggest that the EPHB gene family should not be routinely screened for germline mutations in familial cases, the EPHB genes are candidate tumor suppressors, likely accounting for rare cases of familial colorectal cancer.
###end p 40
###begin title 41
Supporting Information
###end title 41
###begin p 42
(0.06 MB DOC)
###end p 42
###begin p 43
Click here for additional data file.
###end p 43
###begin p 44
(0.05 MB DOC)
###end p 44
###begin p 45
Click here for additional data file.
###end p 45
###begin p 46
The authors thank Dr. D. Daftary, Ms. S. Holter, Ms. A. Janson for their assistance with data collection, and Ms. Joelle Fontaine, Ms. T. Selander and the Mount Sinai Hospital Biospecimen Repository for technical assistance.
###end p 46
###begin title 47
References
###end title 47
###begin article-title 48
Genetic predisposition to colorectal cancer.
###end article-title 48
###begin article-title 49
APC mutations occur early during colorectal tumorigenesis.
###end article-title 49
###begin article-title 50
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
###end article-title 50
###begin article-title 51
Frequent activation of the beta-catenin-Tcf signaling pathway in nonfamilial colorectal carcinomas with microsatellite instability.
###end article-title 51
###begin article-title 52
Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB.
###end article-title 52
###begin article-title 53
EphB/EphrinB receptors and Wnt signaling in colorectal cancer.
###end article-title 53
###begin article-title 54
###xml 105 110 <span type="species:ncbi:9606">human</span>
Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer.
###end article-title 54
###begin article-title 55
Prognostic value of chromosome 1p allelic loss in colon cancer.
###end article-title 55
###begin article-title 56
Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors.
###end article-title 56
###begin article-title 57
EphB2 is a prognostic factor in colorectal cancer.
###end article-title 57
###begin article-title 58
###xml 77 82 <span type="species:ncbi:9606">human</span>
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.
###end article-title 58
###begin article-title 59
###xml 96 99 <span type="species:ncbi:9606">men</span>
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.
###end article-title 59
###begin article-title 60
Ontario familial colon cancer registry: methods and first-year response rates.
###end article-title 60
###begin article-title 61
Susceptibility to leprosy is associated with PARK2 and PACRG.
###end article-title 61
###begin article-title 62
Immunolocalization of the Nuk receptor tyrosine kinase suggests roles in segmental patterning of the brain and axonogenesis.
###end article-title 62
###begin article-title 63
Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells.
###end article-title 63
###begin article-title 64
###xml 30 36 <span type="species:ncbi:9913">bovine</span>
Complete primary structure of bovine plasma fibronectin.
###end article-title 64
###begin article-title 65
Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region.
###end article-title 65
###begin article-title 66
Eph receptor signalling casts a wide net on cell behaviour.
###end article-title 66
###begin article-title 67
Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis.
###end article-title 67
###begin article-title 68
EphB receptors coordinate migration and proliferation in the intestinal stem cell niche.
###end article-title 68
###begin article-title 69
EphB receptor activity suppresses colorectal cancer progression.
###end article-title 69
###begin article-title 70
Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer.
###end article-title 70
###begin article-title 71
###xml 27 35 <span type="species:ncbi:9606">patients</span>
EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis.
###end article-title 71
###begin p 72
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 72
###begin p 73
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the National Cancer Institute, National Institutes of Health under RFA # CA-96-011 (to SG) and through cooperative agreements with members of the Colon Cancer Family Registry and P.I.s. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating institutions or investigators in the Colon CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the Colon CFR. Cancer Care Ontario, as the host organization to the ARCTIC Genome Project, acknowledges that this Project was partly funded by Genome Canada through the Ontario Genomics Institute, by Genome Quebec, the Ministere du Developpement yconomique et Regional et de la Recherche du Quebec and the Ontario Institute for Cancer Research. GZ is a Scholar of the Society of University Surgeons and a recipient of a Terry Fox Foundation Research Fellowship from the National Cancer Institute of Canada. TJH is a recipient of a Clinician-Scientist Award in Translational Research from the Burroughs Wellcome Fund.
###end p 73

